Aldesleukin
Generic name: Aldesleukin
Brand names: Proleukin
Dosage form: intravenous powder for injection (22000000 intl units)
Usage of Aldesleukin
Aldesleukin is used to treat kidney cancer or skin cancer than has spread to other parts of the body.
Aldesleukin may also be used for purposes not listed in this medication guide.
Aldesleukin side effects
Get emergency medical help if you have signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Tell your doctor right away if you have signs of a serious side effect called capillary leak syndrome: stuffy or runny nose followed by tiredness or dizziness, thirst, decreased urination, trouble breathing, and sudden swelling or weight gain.
Aldesleukin may cause serious side effects. Call your doctor at once if you have:
Common side effects of aldesleukin may include:
This is not a complete list of side effects and others may occur. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
Before taking Aldesleukin
You should not be treated with aldesleukin if you are allergic to aldesleukin or interleukin-2, or if:
You may not be able to receive aldesleukin if you've had any of these side effects while receiving aldesleukin in the past:
Tell your doctor if you have ever had:
Tell your doctor if you are pregnant or breastfeeding.
How to use Aldesleukin
Usual Adult Dose for Renal Cell Carcinoma:
0.037 mg/kg (600,000 IU/kg) every 8 hours via a 15-minute IV infusion for a maximum of 14 doses; the schedule is repeated for another 14 doses after 9 days of rest.Maximum Dose: 28 doses per course, as toleratedTherapy Duration: During the first therapy course, metastatic RCC patients received a median of 20 doses and metastatic melanoma patients received a median of 18 doses.Comments: -Each treatment course consists of two 5-day treatment cycles separated by a rest period.-Patient selection should include assessment of ECOG PS (Eastern Cooperative Oncology Group performance status).Uses:-Metastatic melanoma-Metastatic renal cell carcinoma (metastatic RCC)
Usual Adult Dose for Melanoma -- Metastatic:
0.037 mg/kg (600,000 IU/kg) every 8 hours via a 15-minute IV infusion for a maximum of 14 doses; the schedule is repeated for another 14 doses after 9 days of rest.Maximum Dose: 28 doses per course, as toleratedTherapy Duration: During the first therapy course, metastatic RCC patients received a median of 20 doses and metastatic melanoma patients received a median of 18 doses.Comments: -Each treatment course consists of two 5-day treatment cycles separated by a rest period.-Patient selection should include assessment of ECOG PS (Eastern Cooperative Oncology Group performance status).Uses:-Metastatic melanoma-Metastatic renal cell carcinoma (metastatic RCC)
Warnings
You should not be treated with aldesleukin if you have recently had abnormal lung or heart function tests.
Tell your doctor right away if you have signs of a serious side effect called capillary leak syndrome: stuffy or runny nose followed by tiredness or dizziness, thirst, decreased urination, trouble breathing, and sudden swelling or weight gain.
Also tell your doctor if you feel very drowsy during treatment.
What other drugs will affect Aldesleukin
Aldesleukin can harm your kidneys, especially if you also use certain medicines for infections, cancer, osteoporosis, organ transplant rejection, bowel disorders, high blood pressure, or pain or arthritis (including Advil, Motrin, and Aleve).
Using aldesleukin with other drugs that make you drowsy can worsen this effect. Ask your doctor before using opioid medication, a sleeping pill, a muscle relaxer, or medicine for anxiety or seizures.
Many drugs can affect aldesleukin. This includes prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible interactions are listed here. Tell your doctor about all your current medicines and any medicine you start or stop using.
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions